A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0 – Endpoints News
Endpoints News |
A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0
Endpoints News Olivier Danos' arrival as head of Biogen's gene therapy group two-and-a-half years ago signaled an important shift in the big biotech's R&D focus. In swift order Biogen executed a partnership with the San Raffaele-Telethon Institute for Gene Therapy … Regenxbio (RGNX) Names Olivier Danos, Ph.D as Chief Scientific Officer |
